August 2023 in “Journal of The American Academy of Dermatology” Early treatment is key for permanent hair loss disorders, with options ranging from medications and phototherapy to immunomodulators and antibiotics, depending on severity and type.
July 2023 in “Dermatology and therapy” People with alopecia areata may have a higher risk of blood clots.
January 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
January 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
December 2021 in “Journal of The American Academy of Dermatology” COVID-19 can cause different types of hair loss, which may last up to 100 days, and treatments are still being explored.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
Hair loss can be caused by hormones, illness, autoimmune disorders, or vitamin deficiencies, and treatments vary depending on the type.
5 citations,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
1 citations,
November 2017 in “Dermatologic therapy” JAK inhibitors show promise as a future treatment for hair loss.
August 2023 in “International journal of research in dermatology” Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
September 2014 in “SciBX” JAK inhibitors may help treat alopecia areata and promote hair regrowth.
11 citations,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
6 citations,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
37 citations,
May 2016 in “Deutsches Arzteblatt International” Hair loss requires customized treatments based on its various causes and types.
3 citations,
August 2021 in “Veterinary dermatology” New treatments for hair loss are emerging as we better understand hair growth and its genetic causes.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.
October 2020 in “Revista médica sinergía/Revista médica sinergia” Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
41 citations,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
June 2024 in “Bőrgyógyászati és Venerológiai Szemle” New treatments for hair loss, like JAK inhibitors, PRP, anti-androgens, and minoxidil, offer better options.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
September 2023 in “Journal of the American Academy of Dermatology” Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
16 citations,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
6 citations,
June 2016 in “Experimental Dermatology” Frontal Fibrosing Alopecia is a poorly understood condition that is hard to treat and causes distressing hair loss.
2 citations,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
1 citations,
May 2023 in “Prospects in Pharmaceutical Sciences” New cytokine-targeted therapies show promise for treating alopecia areata.
1 citations,
June 2018 in “International Journal of Dermatology” DNCB is highly effective for treating alopecia areata with minimal long-term side effects.